Table 1. Characteristics of the human glioma cohort.
rs6971, TSPO polymorphism rs6971 (77); LAB, low-affinity binding status; MAB, medium-affinity binding status; HAB, high-affinity binding status; Dx, diagnosis; IDH, isocitrate dehydrogenase mutation; m, male; f, female; y, years. See table S1 for supplementary data.
| ID | Age (y) | Sex | Dx | Disease duration (months) | WHO grade | rs6971 | IDH | Sample acquisition | Previous therapy | [18F]GE-180 TSPO-PET |
|---|---|---|---|---|---|---|---|---|---|---|
| #1 | 36.0 | m | Astrocytoma | 5.6 | 2 | HAB | + | Resection | − | + |
| #2 | 59.0 | f | Oligodendroglioma | 13.6 | 2 | MAB | + | Resection | + | + |
| #3 | 50.6 | f | Glioblastoma | 0.9 | 4 | MAB | − | Resection | + | + |
| #4 | 46.9 | f | Oligodendroglioma | 0.3 | 2 | HAB | + | Resection | − | + |
| #5 | 75.7 | f | Glioblastoma | 0.2 | 4 | MAB | − | Biopsy | − | + |
| #6 | 69.1 | f | Glioblastoma | 1.0 | 4 | LAB | − | Resection | + | − |
| #7 | 64.3 | f | Oligodendroglioma | 17.8 | 2 | − | + | Biopsy | + | − |
| #8 | 59.3 | m | Astrocytoma | 2.6 | 2 | HAB | + | Biopsy | + | + |
| #9 | 36.4 | f | Oligodendroglioma | 1.1 | 2 | HAB | + | Biopsy | − | + |
| #10 | 44.0 | m | Oligodendroglioma | 12.3 | 3 | MAB | + | Biopsy | + | + |
| #11 | 72.3 | f | Glioblastoma | 0.1 | 4 | − | − | Resection | − | − |
| #12 | 39.7 | f | Astrocytoma | 4.5 | 2 | − | + | Biopsy | − | − |
| #13 | 27.2 | f | Astrocytoma | 0.7 | 2 | − | + | Biopsy | − | − |
| #14 | 68.7 | m | Glioblastoma | 0.1 | 4 | LAB | − | Resection | − | + |
| #15 | 66.8 | f | Oligodendroglioma | 25.9 | 2 | − | + | Resection | + | − |
| #16 | 58.5 | m | Astrocytoma | 20.8 | 3 | − | + | Biopsy | + | + |
| #17 | 52.8 | f | Oligodendroglioma | 20.9 | 3 | HAB | + | Biopsy | + | + |
| #18 | 49.6 | m | Oligodendroglioma | 1.2 | 3 | HAB | + | Biopsy | + | + |
| #19 | 57.9 | m | Astrocytoma | 12.9 | 3 | MAB | + | Biopsy | + | − |
| #20 | 72.0 | m | Glioblastoma | 1.4 | 4 | HAB | − | Resection | − | + |